Ligands of Immunopharmacology

HS271 is a highly potent, orally active and selective IRAK4 inhibitor, with an IC 50 of 7.2 μM. HS271 exhibits superior enzymatic and cellular activities, as well as excellent pharmacokinetic propertiesIn VivoHS271 (15-150 mg/kg) displays robust in

HS271 is a highly potent, orally active and selective IRAK4 inhibitor, with an IC 50 of 7.2 μM. HS271 exhibits superior enzymatic and cellular activities, as well as excellent pharmacokinetic propertiesIn VivoHS271 (15-150 mg/kg) displays robust in

HS271 is a highly potent, orally active and selective IRAK4 inhibitor, with an IC 50 of 7.2 μM. HS271 exhibits superior enzymatic and cellular activities, as well as excellent pharmacokinetic propertiesIn VivoHS271 (15-150 mg/kg) displays robust in

HS271 is a highly potent, orally active and selective IRAK4 inhibitor, with an IC 50 of 7.2 μM. HS271 exhibits superior enzymatic and cellular activities, as well as excellent pharmacokinetic propertiesIn VivoHS271 (15-150 mg/kg) displays robust in

Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity.Form:Solid

Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity.Form:Solid

Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity.Form:Solid

Human PD-L1 inhibitor IV, a polypeptide, is a competitive human PD-1 protein inhibitor with a K d value of 1.38 μM. Human PD-L1 inhibitor IV inhibits the interaction of hPD-1/hPD-L1Form:SolidIC50&amp Target:Kd: 1.38 μM (Human PD-1 protein)

Human PD-L1 inhibitor IV, a polypeptide, is a competitive human PD-1 protein inhibitor with a K d value of 1.38 μM. Human PD-L1 inhibitor IV inhibits the interaction of hPD-1/hPD-L1Form:SolidIC50&amp Target:Kd: 1.38 μM (Human PD-1 protein)

Human PD-L1 inhibitor IV, a polypeptide, is a competitive human PD-1 protein inhibitor with a K d value of 1.38 μM. Human PD-L1 inhibitor IV inhibits the interaction of hPD-1/hPD-L1Form:SolidIC50&amp Target:Kd: 1.38 μM (Human PD-1 protein)

Human PD-L1 inhibitor V TFA, a human PD-1 protein binding peptide with a K d value of 3.32 μM. Human PD-L1 inhibitor V TFA inhibit the interaction of hPD-1/hPD-L1.Appearance:SolidIn Vitro:Human PD-L1 inhibitor V (Ar5M_2) is a peptide designed with

IACS-8803 diammonium is a highly potent cyclic dinucleotide STING agonist. IACS-8803 diammonium has a robust systemic antitumor efficacy.Appearance:SolidIn Vivo:IACS-8803 diammonium (10 µg intra-tumoral injection) shows superior antitumor activity